Development and applications of surface plasmon resonance-based von Willebrand factor-collagen binding assay

被引:7
作者
Saenko, E
Kannicht, C
Loster, M
Sarafanov, A
Khrenov, A
Kouiavskaia, D
Shima, M
Ananyeva, N
Schwinn, H
Gruber, G
Josic, D
机构
[1] Amer Red Cross, Holland Lab, Rockville, MD 20855 USA
[2] Free Univ Berlin, Inst Mol Biol & Biochem, D-14195 Berlin, Germany
[3] Nara Med Univ, Dept Pediat, Kashihara, Nara 6348522, Japan
[4] Octapharma AG, CH-8853 Lachen, Switzerland
[5] Octapharma Pharmazeut, A-1100 Vienna, Austria
关键词
D O I
10.1006/abio.2001.5555
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Von Willebrand factor (vWf) functions both as a carrier of factor VIII (fVIII) in plasma and as an adhesive protein providing the primary link between collagen of the extracellular matrix and platelets sequestered from blood flow. The functional activity of vWf correlates with the level of its binding to collagen, which is commonly measured in the enzyme-linked immunosorbent assay (ELISA). We developed an automated collagen-binding assay employing the surface plasmon resonance (SPR) phenomenon, which allows one to quantitatively measure the binding of purified vWf and vWf-containing therapeutic fVIII concentrates to collagen type M immobilized on a biosensor chip. The results of the SPR-based assay highly correlated (r = 0.987) with collagen-binding ELISA. The advantages of the SPR-based assay are its higher accuracy and reproducibility in comparison with ELISA. We applied the developed assay for monitoring structural changes in the vWf component of plasma-derived fVIII/vWf concentrates during a virus inactivation procedure performed by heat treatment. We determined the critical residual moisture content of 2% that can be present in lyophilized concentrates during heat-treatment procedures without causing deteriorative changes in vWf properties. Our data suggest that the SPR-based assay is a useful tool in the development of industrial virus-inactivation procedures, allowing one to preserve vWf activity and achieve the maximal therapeutic efficacy of fVIII/vWf concentrates. (C) 2002 Elsevier Science (USA).
引用
收藏
页码:252 / 262
页数:11
相关论文
共 48 条
[1]   SIMPLE METHOD FOR PREPARATION OF HOMOGENEOUS PHOSPHOLIPID VESICLES [J].
BARENHOLZ, Y ;
GIBBES, D ;
LITMAN, BJ ;
GOLL, J ;
THOMPSON, TE ;
CARLSON, FD .
BIOCHEMISTRY, 1977, 16 (12) :2806-2810
[2]   Antigenicity of putative phospholipid membrane-binding residues in factor VIII [J].
Barrow, RT ;
Healey, JF ;
Jacquemin, MG ;
Saint-Remy, JMR ;
Lollar, P .
BLOOD, 2001, 97 (01) :169-174
[3]   STRUCTURE OF PRE-PRO-VON WILLEBRAND FACTOR AND ITS EXPRESSION IN HETEROLOGOUS CELLS [J].
BONTHRON, DT ;
HANDIN, RI ;
KAUFMAN, RJ ;
WASLEY, LC ;
ORR, EC ;
MITSOCK, LM ;
EWENSTEIN, B ;
LOSCALZO, J ;
GINSBURG, D ;
ORKIN, SH .
NATURE, 1986, 324 (6094) :270-273
[4]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[5]   HUMAN VONWILLEBRAND-FACTOR - A MULTIVALENT PROTEIN COMPOSED OF IDENTICAL SUBUNITS [J].
CHOPEK, MW ;
GIRMA, JP ;
FUJIKAWA, K ;
DAVIE, EW ;
TITANI, K .
BIOCHEMISTRY, 1986, 25 (11) :3146-3155
[6]   INTERACTION OF THE VON-WILLEBRAND-FACTOR (VWF) WITH COLLAGEN - LOCALIZATION OF THE PRIMARY COLLAGEN-BINDING SITE BY ANALYSIS OF RECOMBINANT VWF A DOMAIN POLYPEPTIDES [J].
CRUZ, MA ;
YUAN, HB ;
LEE, JR ;
WISE, RJ ;
HANDIN, RI .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (18) :10822-10827
[7]   Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100 degrees C [J].
Dichtelmuller, H ;
Rudnick, D ;
Breuer, B ;
Kotitschke, R ;
Kloft, M ;
Darling, A ;
Watson, E ;
Flehmig, B ;
Lawson, S ;
Frosner, G .
BIOLOGICALS, 1996, 24 (02) :125-130
[8]  
*EUR PHARM COMM, 2000, EUR PHARMACOPOEIA T, V3, P180
[9]  
Ewenstein BM, 1997, ANNU REV MED, V48, P525
[10]   Detection of von Willebrand disorder and identification of qualitative von Willebrand factor defects - Direct comparison of commercial ELISA-based von Willebrand factor activity options [J].
Favaloro, EJ .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 114 (04) :608-618